Tag: Turn.bio

Turn Biotechnologies has unveiled data at four industry conferences suggesting that a single ERA treatment may be more effective than combination therapies used today. Biomarker analysis demonstrates ERA’s regenerative impact on fibroblast proliferation, collagen VII production, and the eTurna™ lipid-based delivery platform proves groundbreakingly effective at reaching targeted tissue. The company plans to present updated...

Turn.bio has announced that its proprietary cellular reprogramming technology was able to significantly increase the proliferative and cytotoxic potential of premanufactured CAR-T cells in vitro. Turn.bio, a developer of mRNA-based cellular reprogramming technologies, has announced preliminary results from its current trial. The announcement was made by the company's co-founder, Prof. Vittorio Sebastiano, at the New...

Marking one of VitaDAO’s largest investments to date, the decentralized organization has allocated $1,000,000 in funding to Turn.Bio. This company, also known as Turn Biotechnologies, plans to undertake preclinical efficacy testing of mRNA therapeutics intended to induce self-healing of the skin and eyes. Through this purchase of an equity stake, VitaDAO is investing into the...

Vittorio Sebastiano is an Associate Professor (Research) of Obstetrics and Gynecology at Stanford University and one of the most prominent scientists in the emerging field of cellular reprogramming. He is also co-founder and Scientific Advisory Board Chairman of Turn Biotechnologies, a cellular rejuvenation company based on the research done in Sebastiano’s Stanford lab. Turn recently...

We recently attended the Undoing Aging Conference in Berlin and had the opportunity to interview Professor Vittorio Sebastiano of Turn.Bio, a company developing partial cellular reprogramming techniques to reverse cellular aging. As we age, our cells experience changes to their epigenetic markers, and this, in turn, changes gene expression, which is proposed to be a...